Compare Abeona Therapeutics Inc (ABEO) vs Enphase Energy Inc (ENPH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Enphase Energy Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Enphase Energy Inc trades at $42.92 (market cap $5.67B). The key difference: Enphase Energy Inc is far larger — about 15.2× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | ENPH | |
|---|---|---|
Market Cap | $373.32M | $5.67B |
Sector | Health | Technology |
52-Week High | $7.23 | $72.33 |
52-Week Low | $4.17 | $26.12 |
Enterprise Value | $228.22M | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ENPH trades at $42.99, down 0.19% on the day, with a bearish technical signal from moving averages. The company reported Q1 2026 EPS of $0.47, beating expectations, but revenue declined to $1.47B in 2025 from $2.3B in 2023. Recent news highlights its entry into AI data center power standards and new product launches, including IQ9N microinverters.
Outlook is mixed: analyst consensus is a 'Hold' with a $41.61 price target, below the current price. Opportunities include expansion into AI-driven energy solutions, but risks involve revenue volatility, high valuation multiples, and competitive pressures in the solar sector. Net cash flow remains positive but has weakened from prior years.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →
